Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 4/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 5/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | DRD3 | P35462 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14991191 | 0.86 | APP (0.59) | MAPTKDM4EGAAALDH1A1MEN1 | |
| SCHEMBL29389131 | 0.84 | GAA (0.58) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL19644103 | 0.84 | GAA (0.58) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL31254773 | 0.83 | MAPT (0.55) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL12297639 | 0.82 | ALDH1A1 (0.55) | MAPTKDM4ENPC1GAAALDH1A1 | |
| SCHEMBL8427633 | 0.81 | ALDH1A1 (0.54) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL643536 | 0.81 | POLB (0.75) | MAPTKDM4EGAAALDH1A1MEN1 | |
| SCHEMBL19659980 | 0.81 | KMT2A (0.64) | MAPTKDM4EGAAALDH1A1MEN1 | |
| SCHEMBL8425552 | 0.80 | POLB (0.55) | MAPTKDM4ENPC1RAB9AGAA | |
| SCHEMBL15691858 | 0.80 | APP (0.53) | MAPTKDM4ENPC1RAB9AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3684354-B1 | XPA INHIBITOR COMPOUNDS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220089577-A1 | KU INHIBITORS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3463371-B1 | KU INHIBITORS AND THEIR USE | UNIV INDIANA RES & TECH CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| US-11207296-B2 | XPA inhibitor compounds and their use | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | NOBELPHARMA CO., LTD. (JP) | 2021-05-06 | — | — | US | disclosed |
| CN-112118839-A | Pyrazolone derivative-containing drug | 耐贝医药株式会社 | 2020-12-22 | — | — | CN | disclosed |
| US-20200308154-A1 | KU INHIBITORS AND THEIR USE | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-10-01 | — | — | US | disclosed |
| EP-3684354-A1 | XPA INHIBITOR COMPOUNDS AND THEIR USE | Indiana University Research and Technology Corporation (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200222367-A1 | XPA INHIBITOR COMPOUNDS AND THEIR USE | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2020-07-16 | — | — | US | disclosed |
| EP-3666270-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | Nobelpharma Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| EP-1553087-A1 | PREVENTIVE AND/OR THERAPEUTIC DRUGS FOR INFLAMMATORY INTESTINAL DISEASES | Mitsubishi Pharma Corporation (JP) | 2005-07-13 | — | — | EP | disclosed |
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040254234-A1 | Medicament for prevention and/or therapy of arterial wall disorder | MITSUBISHI PHARMA CORPORATION (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1437137-A1 | DRUGS COMPRISING COMBINATION OF ANTITHROMBOTIC AGENT WITH PYRAZOLONE DERIVATIVE | Mitsubishi Pharma Corporation (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-RE35801-E | PYRAZOLONE DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-05-19 | — | — | US | disclosed |
| EP-0208874-B1 | PROPHYLACTIC AND THERAPEUTIC AGENT FOR CIRCULATORY DISORDERS | MITSUBISHI KASEI CORPORATION (JP) | 1993-03-24 | — | — | EP | disclosed |
| US-4857542-A | INHIBITOR AGAINST LIPID PEROXIDATION | MITSUBISHI CHEMICAL INDUSTRIES LIMITED (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0208874-A1 | Prophylactic and therapeutic agent for circulatory disorders | MITSUBISHI KASEI CORPORATION (JP) | 1987-01-21 | — | — | EP | disclosed |
| US-3996282-A | Water-soluble quaternary ammonium dyestuffs | STERLING DRUG INC. (US) | 1976-12-07 | — | — | US | disclosed |
| US-3935182-A | Water-soluble quaternary ammonium heterocyclic azo dyestuffs | STERLING DRUG INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254234-A1 | Medicament for prevention and/or therapy of arterial wall disorder | ADRB3, TNNI3, AGTR1 | MAPT 4769/4885KDM4E 3943/4885NPC1 2791/4885 |
| US-20220089577-A1 | KU INHIBITORS AND THEIR USE | ZFR, XRCC6, ZFX | MAPT 3583/4885KDM4E 581/4885NPC1 3278/4885 |
| US-20200222367-A1 | XPA INHIBITOR COMPOUNDS AND THEIR USE | XPOT, XPA, ERCC4 | MAPT 3599/4885KDM4E 1463/4885NPC1 528/4885 |
| US-20050009896-A1 | Particularly 3-methyl-1-phenyl-2-pyrazolin-5-one; thrombolytic agent, an anticoagulant and/or a platelet aggregation inhibitory agent such as a thromboxane synthetase inhibitor; for treating and/or preventing ischemic diseases which are safe and have few side effects | PLAT, PTGIS, SERPINC1 | MAPT 4680/4885KDM4E 3548/4885NPC1 3681/4885 |
| US-11207296-B2 | XPA inhibitor compounds and their use | XPOT, XPA, ERCC4 | MAPT 3599/4885KDM4E 1463/4885NPC1 528/4885 |
| US-20200308154-A1 | KU INHIBITORS AND THEIR USE | ZFR, XRCC6, ZFX | MAPT 3583/4885KDM4E 581/4885NPC1 3278/4885 |
| US-20210128529-A1 | DRUG CONTAINING PYRAZOLONE DERIVATIVE | CYP11B2, CYP3A5, DPYD | MAPT 4271/4885KDM4E 694/4885NPC1 4703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.